

## LITHUANIA

### Recent and planned developments in pharmaceutical policies 2016

#### Special topic: Pricing and reimbursement policies for biosimilars

<b>D E V E L O P M E N T S</b>	<b>Changes in pricing</b>	<b>Changes in reimbursement</b>
	Changes in external reference pricing: refer to the INN cheapest price	New reimbursement procedures for medicines for ultra-rare diseases
<b>S P E C I A L T O P I C</b>	<b>Other changes</b>	
	<ul style="list-style-type: none"> <li>Measures to improve prescribing performance: prescribing quality indicators for diabetes mellitus medicines, cardiovascular medicines preparations</li> <li>Rational prescribing program plan was approved in 2014: different Educational, Economics, Engineering and Enforcement measures will be established in 2015</li> </ul>	
<b>POLICIES FOR BIOSIMILARS</b>		
<p>Reimbursement in the out-patient sector:          The price for biosimilars is set on the same procedure as for generics, i.e. price linkage between originals and follower products.  <i>1st follower:</i> at least 70% priced below originator.  <i>2nd follower:</i> at least 10% priced below 1st follower  <i>3rd follower:</i> at least 10% priced below 2nd follower.</p> <p>Reimbursement in the in-patient sector:          Expensive hospital medicines are included in the List of Centrally Procured Medicines. According to our tendering procedures the cheapest biosimilar product is available for new patients' treatment. Every year the price of biosimilar product is set by tendering procedures. If biosimilar product is available, originator is allowed to prescribe only for treatment continuation.</p> <p>The reimbursement procedure is the same as for all other medicines.</p> <p>In Lithuania, substitution of biosimilars is not allowed.</p>		